Mizuho Securities Co. Ltd. Has $121,000 Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Mizuho Securities Co. Ltd. trimmed its holdings in Illumina, Inc. (NASDAQ:ILMN) by 86.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 870 shares of the life sciences company’s stock after selling 5,580 shares during the quarter. Mizuho Securities Co. Ltd.’s holdings in Illumina were worth $121,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Eukles Asset Management lifted its position in shares of Illumina by 1.7% during the third quarter. Eukles Asset Management now owns 5,942 shares of the life sciences company’s stock worth $816,000 after acquiring an additional 100 shares in the last quarter. Clear Creek Financial Management LLC lifted its position in shares of Illumina by 6.3% during the fourth quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock worth $236,000 after acquiring an additional 100 shares in the last quarter. Lido Advisors LLC lifted its position in shares of Illumina by 6.1% during the third quarter. Lido Advisors LLC now owns 1,859 shares of the life sciences company’s stock worth $255,000 after acquiring an additional 107 shares in the last quarter. Quent Capital LLC lifted its position in shares of Illumina by 45.2% during the fourth quarter. Quent Capital LLC now owns 363 shares of the life sciences company’s stock worth $51,000 after acquiring an additional 113 shares in the last quarter. Finally, Independent Advisor Alliance lifted its position in shares of Illumina by 8.6% during the third quarter. Independent Advisor Alliance now owns 1,595 shares of the life sciences company’s stock worth $219,000 after acquiring an additional 126 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Price Performance

NASDAQ ILMN traded up $4.21 during trading hours on Tuesday, reaching $124.46. 1,302,988 shares of the stock traded hands, compared to its average volume of 1,745,510. The stock has a 50 day simple moving average of $132.79 and a two-hundred day simple moving average of $127.58. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $229.58. The company has a market cap of $19.82 billion, a price-to-earnings ratio of -16.96 and a beta of 1.19. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The firm had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same period last year, the firm earned $0.14 earnings per share. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. On average, analysts predict that Illumina, Inc. will post 0.91 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on ILMN shares. OTR Global restated a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. TD Cowen downgraded Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price objective on the stock. in a research report on Thursday, January 4th. Royal Bank of Canada reiterated an “outperform” rating and issued a $253.00 price objective on shares of Illumina in a research report on Tuesday, April 9th. Stephens reiterated an “overweight” rating and issued a $170.00 price objective on shares of Illumina in a research report on Wednesday, April 10th. Finally, StockNews.com upgraded Illumina from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $167.70.

Insider Activity

In related news, CEO Jacob Thaysen acquired 7,330 shares of Illumina stock in a transaction dated Thursday, February 22nd. The shares were purchased at an average cost of $135.29 per share, with a total value of $991,675.70. Following the completion of the purchase, the chief executive officer now owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.17% of the company’s stock.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.